摘要
2017年美国临床肿瘤学会（ASCO）年会结直肠癌领域共交流289篇摘要，进展颇多，主要包括：（1）早期疾病中Ⅲ期结肠癌术后辅助化疗长短疗程的比较、局部进展期直肠癌全程新辅助治疗策略的应用和腹腔镜直肠癌全系膜切除术的应用。（2）晚期疾病中维生素D3和旧方法选择性内放疗在转移性肠癌治疗中显示出令人鼓舞的疗效，预后极差的特殊群体BRAF突变型患者接受BRAF抑制剂和抗表皮生长因子受体（EGFR）单克隆抗体联合治疗，开创精准治疗的新局面；中国自主研发的小分子激酶抑制剂呋喹替尼和EGFR单克隆抗体生物类似药CMAB009在二线及以后的治疗中展现较好疗效。（3）精准医学及转化研究方面，分子分型共识的临床应用价值初现，液体活组织检查也在术后肿瘤复发监测中展现前景。这些新的治疗和研究进展，将会影响临床实践，推动专业发展，造福患者。
It is plentiful about the 289 abstracts for the colorectal cancer （CRC） in the 2017 annual meeting of the American Society of Clinical Oncology （ASCO）, which include： （1） comparison between long and short courses of postoperative adjuvant chemotherapy for stage Ⅲ CRC in the early diseases, applications of the full course of neoadjuvant therapy for locally advanced rectal cancer and laparoscopic total mesorectal excision for rectal cancer. （2） The use of Vitamin D3 and selective interstitial radiotherapy for metastatic CRC in the advanced diseases showed an encouraging efficacy. Patients with BRAF mutation and poor prognosis underwent a combination therapy of BRAF inhibitor and epidermal growth factor receptor （EGFR）, which has created a new situation for precision therapy. And China′s domestically designed Fruquintinib （small-molecule kinase inhi-bitor） and EGFR CMAB009 have showed better clinical efficacies in the second line therapy. （3） On the precision medicine and translational researches, clinical value of consensus of molecular subtypes is being revealed and liquid biopsy is advantageous to predict postoperative tumor recurrence. These new therapies and researches would impact the clinical practices, promote clinical development and benefit the patients.
作者
陈功
Chen Gong.(Department of Colorectal Surgery, Cancer Center, Sun Yat-sen University, Guangzhou 510060, China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2017年第7期668-673,共6页
Chinese Journal of Digestive Surgery
关键词
结直肠肿瘤
治疗
进展
美国临床肿瘤学会
Colorectal neoplasms
Therapy
Progress
American Society of Clinical Oncology
